Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 25,473

Document Document Title
WO/2019/029295A1
The present invention relates to a pazopanib-based HDAC and VEGFR double-target inhibitor, a preparation method therefor and an application thereof. Said compound has a structure as presented in formula I, II or III. The present inventio...  
WO/2019/027855A1
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or d...  
WO/2019/027765A1
Disclosed are new small molecules having a substituted pyrimidine or substituted fused pyrimidine core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising t...  
WO/2019/027856A1
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or ...  
WO/2019/024845A1
A crystal form of a compound Lemborexant, a preparation method therefor, a pharmaceutical composition comprising the crystal form, and use of the crystal form in the preparation of an orexin receptor antagonist and of a pharmaceutical fo...  
WO/2019/025467A1
The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful fo...  
WO/2019/028055A1
In an aspect, the disclosure provides for compounds (II), compositions, and methods of administering the compounds and compositions to a patient in need thereof. In another aspect, the disclosure relates to compounds and compositions for...  
WO/2019/025275A1
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)propanyl]- and N-[(Pyrazinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them...  
WO/2019/028008A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2019/028357A1
Aspects of the invention relate to compounds, pharmaceutical compositions, methods for the manufacturing of compounds and methods for treatment of various disorders mediated at least in part by one or more galectins.  
WO/2019/022455A1
The present specification relates to a fluorene derivative of chemical formula 1 and an organic light emitting device comprising the same.  
WO/2019/022249A1
The purpose of the present invention is to provide a method for easily raising the transdermal absorption properties of minoxidil without forming a prodrug by organic synthesis. The present invention pertains to: a complex formed from mi...  
WO/2019/023350A1
A composite sorbent composition comprising a polymeric adsorbent; and an extractant having the formula (I), or hydrate thereof, wherein X is O or S, A1 and A2 are each independently -C(O)- or -C(R')(R'')- wherein R', and R'' are each ind...  
WO/2019/023553A1
The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to ...  
WO/2019/016111A1
The invention discloses a method for preparation of 4,6-dichloro-5-nitro-2- (propylthio)pyrimidine by conversion of 5-nitro-2-propylthiopyrimidine-4,6-diol with phosgene in the presence of DMF.  
WO/2019/016293A1
The present invention relates to certain compounds of formula (I) wherein - Ar is (Ar1) or (Ar2) and to their uses as antibacterial agents. The invention further relates to methods of treatment of bacterial infection with such compounds,...  
WO/2019/018359A1
The present disclosure provides compounds, methods, and compositions which may be used to treat tuberculosis. In some embodiments, these compounds and compositions have a bactericidal property against Mycobacterium tuberculosis (Mtb). Me...  
WO/2019/014668A1
Embodiments of the disclosure relate generally to formulations, methods, kits, and dosage forms for improved stability of an active pharmaceutical ingredient, wherein the active ingredient comprises a compound of the formula:(I) wherein ...  
WO/2019/013789A1
Disclosed are compounds of formula I: or pharmaceutically acceptable salts thereof. Compounds of formula I are anti-microbials that inhibit, for instance, Mycobacterium tuberculosis (Mtb) H37Ra. Compounds of formula I also have anti-tube...  
WO/2019/011163A1
Provided are a method for preparing a pyrimidone compound and an important intermediate related in this method. The raw materials of the preparation method are cheap, the reaction condition of preparation method is mild, the preparation ...  
WO/2019/008029A1
The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 ...  
WO/2019/007299A1
Disclosed are a salt and a polymorph of a benzopyrimidinone compound and a pharmaceutical composition and the use thereof. In particular, disclosed are a hydrochloride of a benzopyrimidinone compound as shown in the following formula, (I...  
WO/2019/008593A1
Disclosed here is a process for the preparation of amorphous Rosuvastatin calcium hydrate with high purity.  
WO/2019/010180A1
A method of treating cancer in a subject includes administering to the subject a therapeutically effective amount of a compound, the small molecule having a general formula: A-L-X-Z (I).  
WO/2019/006548A1
A class of fluorinated 2,4-diaminopyrimidine compounds of Formula (I) have been prepared for use in the treatment of cancers and other MERTK related disorders. (Formula (I))  
WO/2019/009093A1
An ethylene compound represented by formula (1) and a resin composition comprising the same. (In formula (1): L represents a divalent or higher-valent linking group; a represents an integer greater than or equal to 2; and A independently...  
WO/2019/008025A1
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...  
WO/2019/002173A1
The present invention relates to a compound of formula (I): wherein the meanings for the various substituents are as disclosed in the description, having dual pharmacological activity towards both the α2δ subunit, in particular the α2...  
WO/2019/005993A1
The present description relates to a method or use of a compound for treating or ameliorating HD (Huntington's Disease) in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I)...  
WO/2019/001396A1
Provided herein are a dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, provided herein is a compound having Formula (I) or (Ia), ...  
WO/2019/005685A1
A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each o...  
WO/2019/006322A1
The present disclosure relates to chemical compounds that inhibit HP1-mediated heterochromatin formation, pharmaceutical compositions containing such compounds, methods of identifying such compounds, and their use in the treatment of dis...  
WO/2019/001420A1
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2018/234808A1
The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.  
WO/2018/234488A1
The present invention relates to cyclopropyl compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their...  
WO/2018/235851A1
The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the Nav1.7 and Nav1.8 channels, and which are useful in the treatment or prevention of disorders and diseases in which ...  
WO/2018/236040A1
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.  
WO/2018/232298A1
The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing a fungus  
WO/2018/232094A1
Disclosed are compounds of formula (I), (II), (III), and (IV), and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula (I)...  
WO/2018/229041A1
The present invention relates to the compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, use of compounds of formula (I) as herb...  
WO/2018/232235A1
A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(l-methyl-lH- indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharma...  
WO/2018/230624A1
The present invention provides: a modified nucleic acid monomer compound having a specific backbone, such as a 2-ethylglycerol or methoxymethyl-1,3-propanediol backbone, instead of the ribose or deoxyribose backbone of a nucleoside; and ...  
WO/2018/224063A2
The invention provides novel solid forms of elagolix and its esters, optionally with acids or with polymers, method of preparation and use thereof. These solid forms are particularly suitable as intermediates of synthesis of elagolix or ...  
WO/2018/223876A1
Provided are a fluorescent probe, a preparation method and application thereof. The fluorescent probe is an addition-activation probe and can be used for specific fluorescent protein labeling, and can also be used for protein quantificat...  
WO/2018/226837A1
We describe the use of comparative structural analysis and structure-guided molecular design to develop potent and selective inhibitors (10d and (S)-17b) of matrix metalloproteinase 13 (MMP-13). We applied a three-step process, starting ...  
WO/2018/225816A1
Provided is a novel compound which has pest control activity for agricultural and horticultural use. The present invention provides: a nitrogen-containing heterocyclic compound represented by formula (1) or a salt thereof; and a bacteric...  
WO/2018/226230A1
The present invention relates generally to methods for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of a small-molecule autophag...  
WO/2018/224063A3
The invention provides novel solid forms of elagolix and its esters of formula (I), optionally with acids or with polymers, methods of preparation and uses thereof. These solid forms are particularly suitable as intermediates of synthesi...  
WO/2018/226622A1
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the presen...  
WO/2018/224060A1
The present invention relates to solid forms with an antimicrobial activity comprising a polysaccharide and triiodide, where the triiodide decomposition to iodide and volatile iodine is significantly suppressed by the presence of a stabi...  

Matches 1 - 50 out of 25,473